{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:36:49Z","timestamp":1792795009278,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.intimp.2021.108078","type":"journal-article","created":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T21:18:11Z","timestamp":1629753491000},"page":"108078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Mechanistic insights into the role of B cells in rheumatoid arthritis"],"prefix":"10.1016","volume":"99","author":[{"given":"Anuja","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapan","family":"Behl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aayush","family":"Sehgal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sukhbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neelam","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanveer","family":"Naved","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saurabh","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Al-Harrasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prasun","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lotfi","family":"Aleya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Vargas-De-La-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Bungau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.108078_b0005","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.cyto.2015.02.007","article-title":"B cells responses and cytokine production are regulated by their immune microenvironment","volume":"74","author":"Vazquez","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.intimp.2021.108078_b0010","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.intimp.2021.108078_b0015","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.intimp.2021.108078_b0020","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/mus.23951","article-title":"Interleukin-10 producing-B cells and their association with responsiveness to rituximab in myasthenia gravis","volume":"49","author":"Sun","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.intimp.2021.108078_b0025","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nm.3554","article-title":"Interleukin-35 induces regulatory B cells that suppress autoimmune disease","volume":"20","author":"Wang","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0030","article-title":"Exploring the therapeutic promise of targeting HMGB1 in rheumatoid arthritis","volume":"258","author":"Kaur","year":"2020","journal-title":"Sciences"},{"issue":"4","key":"10.1016\/j.intimp.2021.108078_b0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.retram.2020.07.003","article-title":"Mechanistic insights into the role of pyroptosis in rheumatoid arthritis","volume":"68","author":"Chadha","year":"2020","journal-title":"Curr. Res. Translational Med."},{"key":"10.1016\/j.intimp.2021.108078_b0040","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.4049\/jimmunol.1700822","article-title":"Transient BAFF blockade inhibits type 1 diabetes development in nonobese diabetic mice by enriching immunoregulatory B lymphocytes sensitive to deletion by anti-CD20 cotherapy","volume":"199","author":"Wang","year":"2017","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0045","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.jaci.2015.10.018","article-title":"IL-10 mediates plasmacytosis-associated immunodeficiency by inhibiting complement-mediated neutrophil migration","volume":"137","author":"Kulkarni","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0050","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/aps.2015.76","article-title":"Prednisone treatment inhibits the differentiation of B lymphocytes into plasma cells in MRL\/MpSlac-lpr mice","volume":"36","author":"Yan","year":"2015","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.intimp.2021.108078_b0055","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1136\/annrheumdis-2014-206016","article-title":"The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus","volume":"74","author":"Alexander","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0060","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.3389\/fimmu.2017.01245","article-title":"Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going?","volume":"8","author":"Marshall","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0065","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s40261-016-0426-7","article-title":"Pharmacokinetics, pharmacodynamics and preliminary observations for clinical activity and safety of multiple doses of human-mouse chimeric anti-CD22 monoclonal antibody (SM03) in Chinese patients with systemic lupus erythematosus","volume":"36","author":"Zhao","year":"2016","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.intimp.2021.108078_b0070","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1002\/art.38736","article-title":"Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis","volume":"66","author":"Glaesener","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.intimp.2021.108078_b0075","doi-asserted-by":"crossref","unstructured":"Mauri C, Bosma A. Immune regulatory function of B cells. Ann Rev Immunol. (2012) 30:221\u201341. doi: 10.1146\/annurev-Immunol-020711-074934Rosser EC, Mauri C. Regulatory B cells: origin, phenotype, and function. Immunity (2015) 42:607\u201312. doi: 10.1016\/j.immuni.2015.04.005.","DOI":"10.1146\/annurev-immunol-020711-074934"},{"issue":"6","key":"10.1016\/j.intimp.2021.108078_b0080","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","article-title":"Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis","volume":"58","author":"Ramwadhdoebe","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.intimp.2021.108078_b0085","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/14737175.2017.1245616","article-title":"Anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"17","author":"Moreno Torres","year":"2017","journal-title":"Expert Rev. Neurother."},{"key":"10.1016\/j.intimp.2021.108078_b0090","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1084\/jem.20130323","article-title":"Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells","volume":"210","author":"Deenick","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0095","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1093\/rheumatology\/kex067","article-title":"Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples","volume":"56","author":"Reddy","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2021.108078_b0100","doi-asserted-by":"crossref","first-page":"R32","DOI":"10.1186\/ar3736","article-title":"Interleukin-10 produced by B cells is crucial for the suppression of Th17\/Th1 responses, induction of T regulatory type 1 cells, and reduction of collagen-induced arthritis","volume":"14","author":"Carter","year":"2012","journal-title":"Arthr Res Therapy"},{"key":"10.1016\/j.intimp.2021.108078_b0105","doi-asserted-by":"crossref","unstructured":"Behl T., Kumar K., Ciprian B., Rus M., et al. Exploring the multifocal role of phytochemicals as immunomodulators, Biomedicine & Pharmacotherapy, Volume 133, 2021,110959, ISSN 0753-3322, https:\/\/doi.org\/10.1016\/j.biopha.2020.110959.","DOI":"10.1016\/j.biopha.2020.110959"},{"key":"10.1016\/j.intimp.2021.108078_b0110","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1136\/annrheumdis-2013-203993","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","volume":"74","author":"Emery","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0115","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.93222","article-title":"Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab","volume":"2","author":"Cho","year":"2017","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.intimp.2021.108078_b0120","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1172\/JCI29470","article-title":"Antibody-enhanced cross-presentation of self-antigen breaks T cell tolerance","volume":"117","author":"Harbers","year":"2007","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.intimp.2021.108078_b0125","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1172\/JCI36800","article-title":"Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans","volume":"119","author":"Chou","year":"2009","journal-title":"Journal of Clinical Investigation"},{"key":"10.1016\/j.intimp.2021.108078_b0130","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1002\/art.40117","article-title":"Antibodies to cyclic citrullinated peptides in patients with juvenile idiopathic arthritis and patients with rheumatoid arthritis: shared expression of the inherently autoreactive 9G4 idiotype","volume":"69","author":"Peckham","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2021.108078_b0135","doi-asserted-by":"crossref","unstructured":"Rosser E., Piper C., Matei D., Blair P., et al. Microbiota-Derived Metabolites Suppress Arthritis by Amplifying Aryl-Hydrocarbon Receptor Activation in Regulatory B Cells, Cell Metabolism, Volume 31,Issue4,2020,Pages837-851.e10,ISSN1550-4131.","DOI":"10.1016\/j.cmet.2020.03.003"},{"key":"10.1016\/j.intimp.2021.108078_b0140","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3899\/jrheum.120583","article-title":"Safety and efficacy of infliximab and adalimumab for refractory uveitis in juvenile idiopathic arthritis: 1-year followup data from the Italian Registry","volume":"40","author":"Zannin","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2021.108078_b0145","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA","volume":"69","author":"Nam","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0150","doi-asserted-by":"crossref","unstructured":"Ruiz Garcia V, Jobanputra P, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Kynaston-Pearson FJB. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. 2014.","DOI":"10.1002\/14651858.CD007649.pub3"},{"key":"10.1016\/j.intimp.2021.108078_b0155","unstructured":"National Institute for Health and Care Excellence (NICE) Adalimumab, etanercept, infliximab, rituximab, and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (Technology Appraisal guidance 195) 2010. pp. 1\u201373."},{"key":"10.1016\/j.intimp.2021.108078_b0160","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1136\/annrheumdis-2011-201117","article-title":"Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis","volume":"72","author":"Isaacs","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0165","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","article-title":"B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: A six-month, national, multicenter, open-label study","volume":"63","author":"Sellam","year":"2011","journal-title":"Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.intimp.2021.108078_b0170","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1161\/CIRCULATIONAHA.109.868158","article-title":"Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice","volume":"120","author":"Lewis","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2021.108078_b0175","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1136\/annrheumdis-2011-201109","article-title":"Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis\u2019 registry","volume":"71","author":"Gottenberg","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0180","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1136\/annrheumdis-2012-201324","article-title":"Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study","volume":"71","author":"Gomez-Reino","year":"2012","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.intimp.2021.108078_b0185","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.clim.2012.01.002","article-title":"IgM autoantibodies to distinct apoptosis-associated antigens correlate with protection from cardiovascular events and renal disease in patients with SLE","volume":"142","author":"Gr\u00f6nwall","year":"2012","journal-title":"Clinical Immunology"},{"issue":"11","key":"10.1016\/j.intimp.2021.108078_b0190","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1002\/eji.201040545","article-title":"Immunoglobulin secretion by B1 cells: differential intensity and IRF4-dependence of spontaneous IgM secretion by peritoneal and splenic B1 cells","volume":"40","author":"Holodick","year":"2010","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108078_b0195","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1084\/jem.20101499","article-title":"Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+CD27+CD43+CD70\u2212","volume":"208","author":"Griffin","year":"2011","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0200","doi-asserted-by":"crossref","unstructured":"Gerlag DM, Safy M, Maijer KI, et al Effects of B-cell directed therapy on the preclinical stage of rheumatoid arthritis: the PRAIRI study Annals of the Rheumatic Diseases 2019;78:179-185.","DOI":"10.1136\/annrheumdis-2017-212763"},{"issue":"8","key":"10.1016\/j.intimp.2021.108078_b0205","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1093\/rheumatology\/ken120","article-title":"Natural antibodies against phosphorylcholine as potential protective factors in SLE","volume":"47","author":"Su","year":"2008","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.intimp.2021.108078_b0210","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1365-2249.2008.03680.x","article-title":"Genetic imprinting of autoantibody repertoires in systemic lupus erythematosus patients","volume":"153","author":"Silverman","year":"2008","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0215","first-page":"1","article-title":"Rituximab versus an alternative TNF inhibitor in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitor: SWITCH-RA, a global, observational, comparative effectiveness study","author":"Emery","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0220","first-page":"S600","article-title":"Mode Of Action Change Not Necessary After Failing The First Tumor Necrosis Factor Inhibitor: Preliminary Results Of a Randomized Controlled Trial","volume":"65","author":"Manders","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.108078_b0225","first-page":"S624","article-title":"Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1st Anti-TNF: Results of the Multicenter Randomized Controlled \u201cROC\u201d Trial","volume":"65","author":"Gottenberg","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.108078_b0230","doi-asserted-by":"crossref","unstructured":"Xiao-Xi Hu, Yu-jing Wu, Jing Zhang, Wei Wei, T-cells interact with B cells, dendritic cells, and fibroblast-like synoviocytes as hub-like key cells in rheumatoid arthritis, International Immunopharmacology, Volume 70,2019, Pages 428-434, ISSN 1567-5769, https:\/\/doi.org\/10.1016\/j.intimp.2019.03.008.","DOI":"10.1016\/j.intimp.2019.03.008"},{"key":"10.1016\/j.intimp.2021.108078_b0235","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s10753-020-01301-1","article-title":"Understanding the Role of Inflammasomes in Rheumatoid Arthritis","volume":"43","author":"Makkar","year":"2020","journal-title":"Inflammation"},{"issue":"7","key":"10.1016\/j.intimp.2021.108078_b0240","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1002\/eji.200636452","article-title":"Antigen presentation and transfer between B cells and macrophages","volume":"37","author":"Harvey","year":"2007","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0245","author":"Shabgah","year":"2019","journal-title":"The role of BAFF and APRIL in rheumatoid arthritis"},{"issue":"6","key":"10.1016\/j.intimp.2021.108078_b0250","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.4049\/jimmunol.174.6.3781","article-title":"Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis","volume":"174","author":"O'Neill","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0255","first-page":"2013","article-title":"The comparative effectiveness of abatacept versus anti-tumour necrosis factor switching for rheumatoid arthritis patients previously treated with an anti-tumour necrosis factor","volume":"2013","author":"Harrold","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0260","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1159\/000082086","article-title":"Regulatory roles for cytokine-producing B cells in infection and autoimmune disease","volume":"8","author":"Lund","year":"2005","journal-title":"Current Directions in Autoimmunity"},{"key":"10.1016\/j.intimp.2021.108078_b0265","doi-asserted-by":"crossref","first-page":"118109","DOI":"10.1016\/j.lfs.2020.118109","article-title":"The endocannabinoid signaling pathway as an emerging target in pharmacotherapy, earmarking mitigation of destructive events in rheumatoid arthritis","volume":"257","author":"Kaur","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.intimp.2021.108078_b0270","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1479-5876-6-72","article-title":"Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it benign?","volume":"27","author":"Tarantino","year":"2008","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0275","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1136\/annrheumdis-2013-204577","article-title":"Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"73","author":"Nam","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0280","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1108188","article-title":"Interleukin-2 and regulatory T cells in graft-versus-host disease","volume":"365","author":"Koreth","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.intimp.2021.108078_b0285","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.retram.2020.05.002","article-title":"Role of Nrf2 in rheumatoid arthritis","volume":"68","author":"Chadha","year":"2020","journal-title":"Curr. Res. Translational Med."},{"key":"10.1016\/j.intimp.2021.108078_b0290","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1146\/annurev.immunol.24.021605.090517","article-title":"B cell immunobiology in disease: evolving concepts from the clinic","volume":"24","author":"Martin","year":"2006","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00011-020-01410-5","article-title":"Untying the correlation between apolipoproteins and rheumatoid arthritis","volume":"70","author":"Makkar","year":"2021","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.intimp.2021.108078_b0300","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.smim.2011.07.004","article-title":"Therapeutic potential of TREGs to treat rheumatoid arthritis","volume":"23","author":"Wright","year":"2011","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0305","doi-asserted-by":"crossref","unstructured":"M. Volkov, K. Schie et al., Autoantibodies and B Cells: The ABC of rheumatoid arthritis pathophysiology 2019 https:\/\/doi.org\/10.1111\/imr.12829.","DOI":"10.1111\/imr.12829"},{"key":"10.1016\/j.intimp.2021.108078_b0310","article-title":"Exploring the role of polyphenols in rheumatoid arthritis","author":"Behl","year":"2021","journal-title":"Crit. Rev. Food Sci. Nutr."},{"key":"10.1016\/j.intimp.2021.108078_b0315","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1084\/jem.20121486","article-title":"Monoclonal IgG antibodies generated from joint-derived B cells of RA patients have a strong bias toward citrullinated autoantigen recognition","volume":"210","author":"Amara","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0320","doi-asserted-by":"crossref","unstructured":"D.E. Furst, E.C. Keystone, B. Kirkham, R. Fleischmann, P. Mease, F.C. Breedveld et al., Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008; 67: iii2\u2013 25.","DOI":"10.1136\/ard.2008.100834"},{"key":"10.1016\/j.intimp.2021.108078_b0325","doi-asserted-by":"crossref","unstructured":"K. Thorarinsdottir, A. Camponeschi et al., CD21\u2212\/low B cells associate with joint damage in rheumatoid arthritis patients 2019 https:\/\/doi.org\/10.1111\/sji.1279.","DOI":"10.1111\/sji.12792"},{"key":"10.1016\/j.intimp.2021.108078_b0330","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1093\/jnci\/djn478","article-title":"Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials","volume":"101","author":"Vidal","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.intimp.2021.108078_b0335","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1136\/ard.2006.061002","article-title":"Consensus statement on the use of rituximab in patients with rheumatoid arthritis","volume":"66","author":"Smolen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0340","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1172\/JCI85113","article-title":"Human regulatory B cells in health and disease: therapeutic potential","volume":"127","author":"Mauri","year":"2017","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.intimp.2021.108078_b0345","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.semarthrit.2018.10.007","article-title":"Regulatory B cells: New players in inflammatory and autoimmune rheumatic diseases","volume":"48","author":"Sakkas","year":"2019","journal-title":"Seminars in Arthritis Rheumatism"},{"key":"10.1016\/j.intimp.2021.108078_b0350","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1016\/j.transproceed.2006.06.131","article-title":"Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients","volume":"38","author":"Basse","year":"2006","journal-title":"Transplant Proc."},{"key":"10.1016\/j.intimp.2021.108078_b0355","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1136\/ard.2007.077461","article-title":"Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response","volume":"67","author":"Oren","year":"2008","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.intimp.2021.108078_b0360","first-page":"644","article-title":"Exploiting CD22 To Selectively Tolerize Autoantibody Producing B-Cells in Rheumatoid Arthritis ACS","volume":"14","author":"Bednar","year":"2019","journal-title":"Chem. Biol."},{"key":"10.1016\/j.intimp.2021.108078_b0365","doi-asserted-by":"crossref","first-page":"3295","DOI":"10.1182\/blood-2006-05-021113","article-title":"Rituximab maintenance improves clinical outcome of relapsed\/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial","volume":"108","author":"Van Oers","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.108078_b0370","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1084\/jem.20111675","article-title":"O'ConnorRA, Anderton SM, Bar-Or A, Fillatreau S, Gray D: B cell depletion therapyameliorates autoimmune disease through ablation of IL-6-producing B cells","volume":"209","author":"Barr","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0375","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1002\/art.20858","article-title":"Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial","volume":"52","author":"Sfikakis","year":"2005","journal-title":"Arthritis Rheum."},{"issue":"6","key":"10.1016\/j.intimp.2021.108078_b0380","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1136\/ard.2009.119222","article-title":"Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate","volume":"69","author":"Cohen","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2021.108078_b0385","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.intimp.2018.12.007","article-title":"Regulatory B cells in inflammatory diseases and tumor","volume":"67","author":"Cai","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.intimp.2021.108078_b0390","doi-asserted-by":"crossref","DOI":"10.1007\/s12026-009-8096-7","article-title":"Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets","author":"Anolik","year":"2009","journal-title":"Immunol. Res."},{"key":"10.1016\/j.intimp.2021.108078_b0395","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104076","article-title":"Regulatory B cells in infection, inflammation, and autoimmunity","volume":"352","author":"Dasgupta","year":"2020","journal-title":"Cellular Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0400","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials","volume":"68","author":"Dougados","year":"2009","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.108078_b0405","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jdermsci.2018.11.008","article-title":"Regulatory and effector B cells: Friends or foes?","volume":"93","author":"Matsushita","year":"2019","journal-title":"J. Dermatological Sci."},{"key":"10.1016\/j.intimp.2021.108078_b0410","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41584-018-0070-0","article-title":"Rheumatoid arthritis and the mucosal origins hypothesis: protection turns to destruction","volume":"14","author":"Holers","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.intimp.2021.108078_b0415","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/art.40401","article-title":"Antibody responses to Citrullinated and Noncitrullinated antigens in the sputum of subjects with rheumatoid arthritis and subjects at risk for development of rheumatoid arthritis","volume":"70","author":"Demoruelle","year":"2018","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.108078_b0420","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1080\/13543784.2016.1249565","article-title":"Developments with investigational Janus kinase inhibitors for rheumatoid arthritis","volume":"25","author":"Semerano","year":"2016","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.intimp.2021.108078_b0425","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13075-017-1505-8","article-title":"Synovial IL-9 facilitates neutrophil survival, function, and differentiation of Th17 cells in rheumatoid arthritis","volume":"20","author":"Chowdhury","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2021.108078_b0430","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.3389\/fimmu.2018.01924","article-title":"T cells that help B cells in chronically inflamed tissues","volume":"9","author":"Rao","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0435","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08916934.2013.856006","article-title":"B cells participate in tolerance and autoimmunity through cytokine production","volume":"47","author":"Luu","year":"2014","journal-title":"Autoimmunity."},{"key":"10.1016\/j.intimp.2021.108078_b0440","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00281-014-0427-7","article-title":"Targeting B cells and autoantibodies in the therapy of autoimmune diseases","volume":"36","author":"Kao","year":"2014","journal-title":"Seminars Immunopathol."},{"key":"10.1016\/j.intimp.2021.108078_b0445","doi-asserted-by":"crossref","first-page":"58","DOI":"10.4049\/jimmunol.154.1.58","article-title":"The growth response to IL-7 during normal human B cell ontogeny is restricted to B-lineage cells expressing CD34","volume":"154","author":"Dittel","year":"1995","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.intimp.2021.108078_b0450","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/BOR.0b013e3282f5e08d","article-title":"New approaches of B-cell-directed therapy: beyond rituximab","volume":"20","author":"D\u00f6rner","year":"2008","journal-title":"Curr. Opin. Rheumatol."},{"issue":"570","key":"10.1016\/j.intimp.2021.108078_b0455","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5327","article-title":"Persistently activated, proliferative memory autoreactive B cells promote inflammation in rheumatoid arthritis","volume":"12","author":"Kristyanto","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.intimp.2021.108078_b0460","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/art.40443","article-title":"Brief report: the genetic profile of rheumatoid factor-positive polyarticular juvenile idiopathic arthritis resembles that of adult rheumatoid arthritis","volume":"70","author":"Hinks","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.intimp.2021.108078_b0465","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.02136","article-title":"Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases","volume":"10","author":"Wei\u00dfenberg","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2021.108078_b0470","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nrd2085","article-title":"B cells move to center stage: novel opportunities for autoimmune disease treatment","volume":"5","author":"Browning","year":"2006","journal-title":"Nat. Rev. Drug Discovery"},{"issue":"5","key":"10.1016\/j.intimp.2021.108078_b0475","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.4049\/jimmunol.181.5.2961","article-title":"B cell depletion with anti-CD79 mAbs ameliorates autoimmune disease in MRL\/lpr mice","volume":"181","author":"Li","year":"2008","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.108078_b0480","doi-asserted-by":"crossref","DOI":"10.1186\/ar2617","article-title":"Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sj\u00f6gren syndrome in salivary glands of non-obese diabetic mice","volume":"11","author":"Gatumu","year":"2009","journal-title":"Arthritis Res. Therapy"},{"issue":"16","key":"10.1016\/j.intimp.2021.108078_b0485","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.intimp.2021.108078_b0490","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1002\/art.23059","article-title":"Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis","volume":"56","author":"Keystone","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2021.108078_b0495","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.intimp.2021.108078_b0500","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2007.083188","article-title":"Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann. Rheum. Dis."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921007141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576921007141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,5]],"date-time":"2024-11-05T20:16:25Z","timestamp":1730837785000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576921007141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":100,"alternative-id":["S1567576921007141"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108078","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into the role of B cells in rheumatoid arthritis","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.108078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108078"}}